LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Akcijų sąrašas・Xencor Inc

Xencor Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

11.81 -1.01

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.81

Max

11.94

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-214M -129M
Pardavimai	-24M 4.5M
Pelnas, tenkantis vienai akcijai	-1.71
Pelno marža	-2,854.65
Darbuotojai	260
EBITDA	-81M -75M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+104.55% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-152M 839M
Ankstesnė atidarymo kaina	12.82
Ankstesnė uždarymo kaina	11.81

Naujienos nuotaikos

By Acuity

34%

66%

75 / 344 reitingas Healthcare

Xencor Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-29 23:08; UTC

Įsigijimai, susijungimai, perėmimai

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

2026-05-29 23:06; UTC

Įsigijimai, susijungimai, perėmimai

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

2026-05-29 20:53; UTC

Uždarbis

Oil Declines Lift Stocks to Fresh Records -- WSJ

2026-05-29 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-05-29 20:33; UTC

Rinkos pokalbiai

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

2026-05-29 20:11; UTC

Uždarbis

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026-05-29 19:47; UTC

Uždarbis

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

2026-05-29 19:36; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures End Month With Gains -- Market Talk

2026-05-29 19:34; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-29 19:34; UTC

Rinkos pokalbiai

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

2026-05-29 19:22; UTC

Rinkos pokalbiai

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

2026-05-29 19:05; UTC

Įsigijimai, susijungimai, perėmimai

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

2026-05-29 18:19; UTC

Rinkos pokalbiai

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

2026-05-29 18:12; UTC

Įsigijimai, susijungimai, perėmimai

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

2026-05-29 18:11; UTC

Rinkos pokalbiai

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

2026-05-29 18:10; UTC

Rinkos pokalbiai

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

2026-05-29 17:55; UTC

Uždarbis

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026-05-29 17:55; UTC

Rinkos pokalbiai

NEAR Protocol Nearly Doubles in May -- Market Talk

2026-05-29 17:38; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

2026-05-29 17:00; UTC

Uždarbis

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

2026-05-29 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-29 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-05-29 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-05-29 16:02; UTC

Rinkos pokalbiai

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

2026-05-29 15:55; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-29 15:55; UTC

Rinkos pokalbiai

Cryptocurrencies Appear Detached From Stocks -- Market Talk

2026-05-29 15:50; UTC

Įsigijimai, susijungimai, perėmimai

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

2026-05-29 15:50; UTC

Įsigijimai, susijungimai, perėmimai

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

2026-05-29 15:40; UTC

Rinkos pokalbiai

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

2026-05-29 15:20; UTC

Rinkos pokalbiai

Canada's Economy Not Looking All That Bright -- Market Talk

Akcijų palyginimas

Kainos pokytis

Xencor Inc Prognozė

Kainos tikslas

By TipRanks

104.55% į viršų

12 mėnesių prognozė

Vidutinis 24.3 USD 104.55%

Aukščiausias 38 USD

Žemiausias 13 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Xencor Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Xencor Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

75 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.